Serafima Glouzgal, MD
Internal Medicine · Ridgefield, CTNPI 1497785166
Payments from drug & device makers
Across 104 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$252
- Pfizer$225
- Novartis$206
- Astellas Pharma US Inc$184
- AbbVie$163
- AstraZeneca$150
- plus $878 from 17 others
What the payments were for
- Food & beverage$1,99397%
- Education$653%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 12 | $252 |
| Pfizer | 10 | $225 |
| Novartis | 9 | $206 |
| Astellas Pharma US Inc | 9 | $184 |
| AbbVie(2 entities) | 8 | $163 |
| AstraZeneca | 10 | $150 |
| Amgen | 1 | $125 |
| Amarin Pharma, Inc. | 7 | $120 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $96 |
| Kowa Pharmaceuticals America, Inc. | 7 | $96 |
| Boehringer Ingelheim | 4 | $83 |
| Exact Sciences | 3 | $79 |
| Johnson & Johnson | 4 | $55 |
| Amneal Pharmaceuticals LLC | 2 | $40 |
| Collegium Pharmaceutical, Inc. | 2 | $32 |
| Sumitomo Pharma America, Inc. | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Mayne Pharma Commercial LLC | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| IBSA Pharma Inc. | 1 | $17 |
| Therapeuticsmd, Inc. | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Seqirus USA Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$125
How this compares
$2,058 in reported general payments places this provider in the 80th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 412 | $131,635 |
| XifaxanRifaximin | 46 | $38,830 |
| MyrbetriqMirabegron | 174 | $38,338 |
| OzempicSemaglutide | 28 | $28,490 |
| XareltoRivaroxaban | 188 | $27,549 |
| JardianceEmpagliflozin | 125 | $22,994 |
| VeltassaPatiromer Calcium Sorbitex | 19 | $10,722 |
| LivaloPitavastatin Calcium | 11 | $10,693 |
| FarxigaDapagliflozin Propanediol | 22 | $10,689 |
| JanuviaSitagliptin Phosphate | 21 | $10,568 |
| RexultiBrexpiprazole | 24 | $8,573 |
| GemtesaVibegron | 67 | $8,385 |
| VraylarCariprazine Hcl | 22 | $7,647 |
| Atorvastatin Calcium | 986 | $6,599 |
| Levothyroxine Sodium | 636 | $4,949 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $225 | $131,635412 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $20 | $38,83046 claims |
| Astellas Pharma US IncMyrbetriq | $184 | $38,338174 claims |
| Johnson & JohnsonXarelto | $55 | $27,549188 claims |
| Boehringer IngelheimJardiance, Tradjenta | $83 | $27,291183 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $96 | $10,69311 claims |
| AstraZenecaFarxiga | $150 | $10,68922 claims |
| AbbVieVraylar, Synthroid | $163 | $10,51648 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $24 | $8,57324 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $29 | $8,38567 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $40 | $4,949636 claims |
| NovartisEntresto | $206 | $3,67721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in Ridgefield
- Joseph SouferWaterbury$21.5M
- David RadinStamford$7M
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$2.8M
- Charles MontanoCromwell$2.8M
- Arthur DecillisMadison$1M
- Michelle MallitzTrumbull$971K
- Allen HellerWoodbridge$758K
- Gary BlickNorwalk$717K
- Margaret ChusteckaHamden$652K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.